Background-The objective of this study is to evaluate the safety and quality of computed tomographic angiography of the thoracic aorta (CTA-TA) exams performed using intraosseous needle intravenous access (ION-IVA) for contrast media injection (CMI).
Introduction
The majority of victims of major trauma require computed tomographic angiography of the thoracic aorta (CTA-TA) as part of their imaging evaluation. 1 CTA-TA requires intravenous access (IVA) for contrast media injection (CMI) at high flow rates. 2 Peripheral IVA is favored for this purpose, but is not always achievable. 2 In such circumstances, central lines can be used for CMI. 2 In instances when central line placement is inexpedient or impossible, an alternative exists: intraosseous needle intravenous access (ION-IVA) (see Figs 1 and 2 ). ION-IVA placement is safer and faster than central line placement, with a failure rate of less than 1%. 3 A recent clinical review by Baadh et al. calls for imaging physicians to familiarize themselves with the technique of using ION-IVA for CMI. 4 There is a substantial body of mid twentieth century literature, predating the advent of computed tomography, reporting the safe use of ION-IVA for CMI during fluoroscopic venography studies. 5 Fairly recent data on the safe use of ION-IVA for CMI from animal models has also been published. 6, 7 However, modern literature reporting the clinical use of ION-IVA for CTA-TA is sparse. 4, [8] [9] [10] The objective of this study was to retrospectively survey the safety of ION-IVA CMI performed during CTA-TA and to assess the quality of the resultant exams.
Materials and methods
7401 CTA-TA exams, performed between January 1, 2013 and August 14, 2015, were reviewed to create a CTA-TA database. Written informed consent was waived by the Institutional Review Board due to the retrospective nature of the project and because of the large number of exams included in the database. CTA-TA quality measurements were performed from survey series of 3.0 mm thick images. Attenuation and noise were measured within the ascending aorta and nearby adipose tissue using circular region-of-interests of approximately 100 mm. 2 Contrast-to-noise ratio (CNR) for the aorta was derived using the method of Feuchtner et al. 11 Other CTA-TA data collected included technical factors such as site of IVA, CMI rate, CMI dose, scanner type, and reconstruction method. Patient data, such as age, sex, weight, height, and chest width, was collected. The institutional adverse event reporting system was queried for all events related to CTA-TA. Complete chart review was performed for all patients who received CTA-TA exams utilizing ION-IVA.
Statistical analyses were performed using open source "R" statistical software version 3.1.1. Scatterplots and correlation coefficients were used to examine adequacy of a linear association between CNR and covariates of interest. The potential of multicollinearity was assessed with the Pearson correlation coefficient. Multiple linear regression models were fitted with two-way interactions. Backward elimination procedure, F-statistic, and adjusted R squared were used to select parsimonious models. Constant variance, normality, and independence were examined.
Results
17 (~0.2%) of 7401 of the exams performed during the study period utilized ION-IVA. All ION-exams were performed with EZ-IO needles (Teleflex Medical, Limerick, Pennsylvania, U.S.A.). CMI rates for ION-exams varied between 2.5 and 4.0 ml/s (mean of 3.4 ml/s). CMI dose varied between 80 and 100 ml (mean of 91 ml) of Iohexol 350. Mean attenuation for the ION-exams was 312 HU (SD 88 HU) and mean CNR was 25 (SD 9.9). Assessment of attenuation versus other covariates revealed a strong positive linear association between attenuation and CMI rate (R = 0.58, p-value = 0.014) and a strong negative association between attenuation and chest width (R = −0.53, p-value = 0.028). CNR also exhibited a strong negative linear association with chest width (R = −0.77, p-value<0.001). ION-exam and patient data is summarized in Table 1 
Discussion
The use of ION-IVA for CTA-TA during the study period was rare, occurring in only 17 (0.2%) of the 7401 exams performed. (central lines, in contrast, were utilized in 125). This rarity may reflect trepidation of imaging personnel who were confused by or unfamiliar with ION-IVA. However, the study institution has developed a useful algorithm (Fig. 3) for using ION-IVA for CMI. As this and other algorithms 4 are promulgated via the medical literature, training in the use ION-IVA for CTA-TA may become routine. Furthermore, it is promising that in this series no untoward event related to CMI via ION-IVA was observed. As this and similar evidence 4, [8] [9] [10] related to the safety of ION-IVA for CMI mounts, personnel may be less reluctant to use ION-IVA for this indication.
The mean aortic attenuation observed in the ION-exams was 312 HU, exceeding the mean attenuation of exams in the database performed with antecubital access, which was 271 HU. Due to the small sample size of ION-exams, this result should not be considered significant. The ION-exam data demonstrated statistically significant positive linear associations between aortic attenuation and CMI rate. The implication of this association is that, although the vascular anatomy of bone differs from that of superficial soft tissue, these differences do not limit flow, at least for rates less than 4.0 ml/s. Further study will be necessary to determine if this holds true for higher injection rates (e.g. the 5.0-6.0 ml/s rates recommended for cardiac CT).
Intramedullary bone is rich in pain receptors, and there is both the potential for, and anticipation of, pain during prolonged ION-IVA infusions. 3, 12 While it is interesting that during this review no reports of ION-IVA related pain were found, it is important to note that all of the patients studied were either experiencing pain associated this their traumatic injuries, the recipients of IV analgesia, or obtunded at the time of CTA-TA acquisition. Consequentially, pain from their ION-IVA infusions may have been masked or simply not recorded. Prophylactic analgesia is recommended when ION-IVA is used for large volume infusions. 3 
Limitations and bias
This study has notable limitations. It is a single institution observational study that yielded a very small sample size (N = 17). Patients with difficult AC-IVA often suffer from cardiovascular insufficiency, which may have introduced susceptibility bias. Technologist unfamiliarity with ION likely lead to selection bias and may explain the small sample size of this study.
Conclusion
The data presented herein suggests ION-IVA may be an acceptable alternative route for CMI for CTA-TA when peripheral IVA is unavailable or inexpedient. Prospective studies should be performed to validate this finding.
Summary
This study investigated the safety and quality of intraosseous needle intravenous access for contrast injection for Computed Tomographic Angiography of the Thoracic Aorta. A retrospective search of a quality and safety database found 17 studies performed in this manner. A control group, comprised of the studies in the database performed with antecubital intravenous access, was used for comparison. The quality metrics of the two groups were similar, with the intraosseous needle group being slightly better. A review of patient and complication records found no evidence of complications related to intraosseous needle use.
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